View more in

People Who Received J&J Vaccine May Be Better Off With Moderna or Pfizer Booster

The New York Times
The New York Times
 2 days ago
A vial of the COVID-19 vaccine in New York on June 23, 2021. (Bess Adler/The New York Times)

People who received a Johnson & Johnson coronavirus vaccine may be better off with a booster shot from Moderna or Pfizer-BioNTech, according to preliminary data from a federal clinical trial published Wednesday.

That finding, along with a mixed review of Johnson & Johnson’s booster data from the Food and Drug Administration released earlier in the day, could lead to a heated debate about whether and how to offer additional shots to the 15 million Americans who have received the single-dose vaccine.

The agency’s panel of vaccine advisers will meet Friday and vote on whether to recommend that the agency authorize the company’s application for boosters for recipients of its vaccine.

Despite these questions about the strength of J&J boosters, some experts anticipated that the agency would clear the shots anyway to meet the public’s demand.

In a study conducted by the National Institutes of Health, researchers organized nine groups of roughly 50 people. Each group received one of the three authorized vaccines, followed by a booster. In three groups, volunteers received the same vaccine for a boost. In the other six, they switched to a different one.

The researchers found that those who got a Johnson & Johnson shot followed by a Moderna booster saw their antibody levels rise 76-fold within 15 days, whereas those who received another dose of Johnson & Johnson saw only a fourfold rise in the same period. A Pfizer-BioNTech booster raised antibody levels in Johnson & Johnson recipients 35-fold.

Still, the authors cautioned about the study’s small size and noted that they did not follow the volunteers long enough to identify potential rare side effects.

The study was also limited in how it measured the immunity provided by boosters. The researchers only looked for antibodies that can stop the coronavirus from replicating in cells. They did not examine how well the booster trains immune cells to recognize and kill infected cells.

Johnson & Johnson in a statement said it looked forward to discussing the data at the Friday meeting, where panelists will also hear a presentation from the authors of the mix-and-match study.

The FDA has already authorized an additional shot of the Pfizer-BioNTech vaccine for people older than 65 or with health conditions or job exposures that put them at higher risk. Moderna has also submitted an application for a booster, which will be evaluated by the FDA’s advisers Thursday.

This article originally appeared in The New York Times .

Comments / 648

Jerry Barton
2d ago

You do not know the half if it. Why do you think that the thounsands of trained Health care workers preferred to quit a job that they had trained for all of their lives rather then be vaccinated ? Ask yourselves what do they know that you don't?

2d ago

In real news. The Nordic countries are all banning the moderna covid vaccine. Wonder why that isn’t being talked about here 🤔

Tim Marton
2d ago

If you took any of them, you would be better off with covid. Taking the vaccine changes your DNA, which is connected to your immune system Taking the vaccine compromised your immune system, that is why most hospitalized had both shots. You will catch on as your health deteoriates.


Comments / 0